Loading...
Market
How much revenue will Radionetics generate from the Lilly deal by end of 2025?
5
Resolution / Starting Odds
Less than $140 million • 33%
$140 million - $500 million • 33%
More than $500 million • 33%
Financial reports from Radionetics Oncology
Story
Radionetics Oncology Enters $140M Strategic Agreement With Lilly, Acquisition Option for $1B
Jul 1, 2024, 02:51 PM
Radionetics Oncology has entered into a strategic agreement with Eli Lilly and Company. As part of the deal, Radionetics will receive a $140 million upfront payment. In return, Lilly gains the exclusive right to acquire Radionetics for $1 billion. The agreement focuses on enhancing Lilly's cancer drug pipeline with radiopharmaceuticals developed by Radionetics. Lilly inks the deal with the biotech startup to expand its radiopharmaceutical offerings.
View original story
Similar markets
$45.4 billion to $46.6 billion • 25%
Less than $45.4 billion • 25%
More than $46.6 billion • 25%
Between $46.0 billion and $46.6 billion • 25%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%
Below $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
Above $12 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Yes • 50%
No • 50%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $10M • 25%
$10M to $50M • 25%
$50M to $100M • 25%
More than $100M • 25%